课题基金 / 基金详情

PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIBITOR

PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIBITOR
PX-171-001-蛋白酶体抑制剂剂量递增的 I 期研究
批准号：
7625637
负责人：
ROBERT ZYGMUNT ORLOWSKI
金额：
$4.24万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7625637
关键词：
Computer Retrieval of Information on Scientific Projects DatabaseDoseFundingGrantInstitutionInvestigational DrugsLearningPhase I Clinical TrialsProteasome InhibitorPurposeResearchResearch PersonnelResourcesSafetySourceUnited States National Institutes of Healthresearch study

项目摘要

项目成果

ROBERT ZYGMUNT ORLOWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to learn about the safety of an investigational drug called PR-171 at different dose levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA
M. D. Anderson Cancer Center SPORE in Multiple Myeloma
海外基金